BamSEC and AlphaSense Join Forces
Learn More

Spruce Biosciences Inc – Material Contracts

NASDAQ: SPRB    
Share price (3/25/26): $69.97    
Market cap (3/25/26): $96.0 million
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.2
from 8-K 7 pages Spruce Biosciences, Inc. Rsu Award Grant Notice
12/34/56
EX-10.9
from 10-K 4 pages Spruce Biosciences, Inc. Non-Employee Director Compensation Policy
12/34/56
EX-10.1
from 8-K 5 pages Corwin Dale Hooks February 18, 2026 Re: Employment Terms Dear Dale,
12/34/56
EX-10.1
from 8-K 37 pages Form of Securities Purchase Agreement
12/34/56
EX-10.2
from 10-Q 3 pages Certain Identified Information Has Been Excluded From This Exhibit Because It Is Both Not Material and Is the Type That the Registrant Treats as Private or Confidential. Information That Was Omitted Has Been Noted in This Document With a Placeholder Identified by the Mark “[***]”. Twist Bioscience Corporation First Amendment to Antibody Licensing Agreement
12/34/56
EX-10.1
from 8-K 9 pages Purchase Agreement
12/34/56
EX-10.28
from 10-K 81 pages Certain Identified Information Has Been Excluded From This Exhibit Because It Is Both Not Material and Is the Type That the Registrant Treats as Private or Confidential. Information That Was Omitted Has Been Noted in This Document With a Placeholder Identified by the Mark “[***]”. Collaboration and License Agreement Between Hbm Alpha Therapeutics, Inc. and Spruce Biosciences, Inc. January 15, 2025
12/34/56
EX-10.27
from 10-K 58 pages Certain Identified Information Has Been Excluded From This Exhibit Because It Is Both Not Material and Is the Type That the Registrant Treats as Private or Confidential. Information That Was Omitted Has Been Noted in This Document With a Placeholder Identified by the Mark “[***]”. Exclusive License Agreement
12/34/56
EX-10.26
from 10-K 23 pages Certain Identified Information Has Been Excluded From This Exhibit Because It Is Both Not Material and Is the Type That the Registrant Treats as Private or Confidential. Information That Was Omitted Has Been Noted in This Document With a Placeholder Identified by the Mark “[***]”. Antibody License Agreement
12/34/56
EX-10.1
from 10-Q 4 pages Spruce Biosciences, Inc. Non-Employee Director Compensation Policy
12/34/56
EX-10
from 10-K 72 pages Certain Identified Information Has Been Excluded From This Exhibit Because It Is Both Not Material and Is the Type That the Registrant Treats as Private or Confidential. Information That Was Omitted Has Been Noted in This Document With a Placeholder Identified by the Mark “[***]”. Collaboration and License Agreement Between Spruce Biosciences, Inc. and Kaken Pharmaceutical Co., Ltd. January 5, 2023
12/34/56
EX-10
from 10-K 7 pages Spruce Biosciences, Inc. Rsu Award Grant Notice
12/34/56
EX-10.1
from 8-K 57 pages Securities Purchase Agreement
12/34/56
EX-10.2
from 8-K 69 pages Lease Termination Agreement
12/34/56
EX-10.1
from 8-K 45 pages Lease Agreement
12/34/56
EX-10.7
from 10-Q 4 pages Spruce Biosciences, Inc. Non-Employee Director Compensation Policy
12/34/56
EX-10.1
from 8-K 3 pages Re: Amendment to Offer Letter Dear Javier, This Letter Agreement (This “Amendment”) Amends the Offer Letter Dated December 29, 2021 (The “Offer Letter”), Between You and Spruce Biosciences, Inc. (The “Company”), as Set Forth Below. the Eighth Paragraph of the Offer Letter Is Hereby Amended and Restated in Its Entirety as Follows
12/34/56
EX-10.24
from 10-K 5 pages March 14, 2022 Re: Employment Terms Dear Will,
12/34/56
EX-10.23
from 10-K 6 pages Separation and Release Agreement
12/34/56
EX-10.22
from 10-K 40 pages Open Market Sale Agreement
12/34/56